Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
· economictimes.indiatimes.com
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drugs potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock extend recent gains despite technically entering overbought territory after a sharp rally.
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in accou...